Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Por Spadi, Rosella, Brusa, Federica, Ponzetti, Agostino, Chiappino, Isabella, Birocco, Nadia, Ciuffreda, Libero, Satolli, Maria Antonietta
Publicado no World J Clin Oncol (2016)

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

Por Brizzi, Maria P, Berruti, Alfredo, Ferrero, Anna, Milanesi, Enrica, Volante, Marco, Castiglione, Federico, Birocco, Nadia, Bombaci, Sebastiano, Perroni, Davide, Ferretti, Benedetta, Alabiso, Oscar, Ciuffreda, Libero, Bertetto, Oscar, Papotti, Mauro, Dogliotti, Luigi
Publicado em 2009

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

Por Berruti, Alfredo, Fazio, Nicola, Ferrero, Anna, Brizzi, Maria Pia, Volante, Marco, Nobili, Elisabetta, Tozzi, Lucia, Bodei, Lisa, Torta, Mirella, D’Avolio, Antonio, Priola, Adriano Massimiliano, Birocco, Nadia, Amoroso, Vito, Biasco, Guido, Papotti, Mauro, Dogliotti, Luigi
Publicado em 2014